FindTrial
Sign In

Phase II parallel studies on the use of 3D-radiotherapy plus Amifostine or IMRT to evaluate xerostomia reduction in patients with head and neck cancer treated in definitve or postoperative setting.

Phase II parallel studies on the use of 3D-radiotherapy plus Amifostine or IMRT to evaluate xerostomia reduction in patients with head and neck cancer treated in definitve or postoperative setting.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-004288-31-IT
Enrollment
Unknown
Registered
2007-02-14
Start date
2005-01-28
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

subcutaneous amiphostine with 3D-radiotherapy to reduce xerostomia

Interventions

Trade Name: ETHYOL*IV INFUS 5FL POLV 375MG Pharmaceutical Form: Powder for infusion* INN or Proposed INN: Amifostine CAS Number: 20537-88-6 Concentration unit: mg milligram(s) Concentration type: equa

Sponsors

ISTITUTI FISIOTERAPICI OSPITALIERI
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026